Literature DB >> 7942844

A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

A K Godwin1, L Vanderveer, D C Schultz, H T Lynch, D A Altomare, K H Buetow, M Daly, L A Getts, A Masny, N Rosenblum.   

Abstract

Linkage analysis in familial breast and ovarian cancer and studies of allelic deletion in sporadic ovarian tumors have identified a region on chromosome 17q containing a candidate tumor-suppressor gene (referred to as BRCA1) of likely importance in ovarian carcinogenesis. We have examined normal and tumor DNA samples from 32 patients with sporadic and 8 patients with familial forms of the disease, for loss of heterozygosity (LOH) at 21 loci on chromosome 17 (7 on 17p and 14 on 17q). LOH on 17p was 55% (22/40) for informative 17p13.1 and 17p13.3 markers. When six polymorphic markers flanking the familial breast/ovarian cancer susceptibility locus on 17q12-q21 were used, LOH was 58% (23/40), with one tumor showing telomeric retention. Evaluation of a set of markers positioned telomeric to BRCA1 resulted in the highest degree of LOH, 73% (29/40), indicating that a candidate locus involved in ovarian cancer may reside distal to BRCA1. Five of the tumors demonstrating allelic loss for 17q markers were from individuals with a strong family history of breast and ovarian cancer. More important, two of these tumors (unique patient number [UPN] 57 and UPN 79) retained heterozygosity for all informative markers spanning the BRCA1 locus but showed LOH at loci distal to but not including the anonymous markers CMM86 (D17S74) and 42D6 (D17S588), respectively. Deletion mapping of seven cases (two familial and five sporadic) showing limited LOH on 17q revealed a common region of deletion, distal to GH and proximal to D17S4, that spans approximately 25 cM. These results suggest that a potential tumor-suppressor gene involved in both sporadic and familial ovarian cancer may reside on the distal portion of chromosome 17q and is distinct from the BRCA1 gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942844      PMCID: PMC1918278     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  56 in total

1.  Breast cancer genes: how many, where and who are they?

Authors:  M C King
Journal:  Nat Genet       Date:  1992-10       Impact factor: 38.330

2.  Accumulation of genetic alterations and progression of primary breast cancer.

Authors:  T Sato; F Akiyama; G Sakamoto; F Kasumi; Y Nakamura
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

3.  Inherited breast and ovarian cancer. What are the risks? What are the choices?

Authors:  M C King; S Rowell; S M Love
Journal:  JAMA       Date:  1993-04-21       Impact factor: 56.272

4.  A breast-ovarian cancer susceptibility gene maps to chromosome 17q21.

Authors:  J Feunteun; S A Narod; H T Lynch; P Watson; T Conway; J Lynch; J Parboosingh; P O'Connell; R White; G M Lenoir
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

5.  Chromosome 17q linkage studies of 18 Utah breast cancer kindreds.

Authors:  D E Goldgar; L A Cannon-Albright; A Oliphant; J H Ward; G Linker; J Swensen; T D Tran; P Fields; P Uharriet; M H Skolnick
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

6.  Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21.

Authors:  S A Smith; D F Easton; D Ford; J Peto; K Anderson; D Averill; M Stratton; M Ponder; C Pye; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

7.  Linkage studies with 17q and 18q markers in a breast/ovarian cancer family.

Authors:  B J Milner; L A Allan; K F Kelly; D Cruickshank; M Hall; A Johnston; H Kitchener; D Parkin; N Haites
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

8.  Allelic loss on chromosome 17 in human ovarian cancer.

Authors:  N Phillips; M Ziegler; B Saha; F Xynos
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

9.  Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.

Authors:  W D Foulkes; D M Black; G W Stamp; E Solomon; J Trowsdale
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

10.  Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome.

Authors:  S A Smith; D F Easton; D G Evans; B A Ponder
Journal:  Nat Genet       Date:  1992-10       Impact factor: 38.330

View more
  20 in total

1.  Microsatellite instability and loss of heterozygosity in human pterygia.

Authors:  D A Spandidos; G Sourvinos; H Kiaris; J Tsamparlakis
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.

Authors:  D B Berman; J Wagner-Costalas; D C Schultz; H T Lynch; M Daly; A K Godwin
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

3.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

4.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

5.  Allelic Losses from Chromosome 17 in Human Osteosarcomas.

Authors:  Marianna Sztán; Zsuzsa Pápai; Miklós Szendrôi; Marco van der Looij; Edith Oláh
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

6.  Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.

Authors:  Rudi Henriksen; Flemming Brandt Sørensen; Torben Falck Ørntoft; Karin Birkenkamp-Demtroder
Journal:  Tumour Biol       Date:  2011-03-12

7.  Identification, characterization, and localization to chromosome 17q21-22 of the human TBX2 homolog, member of a conserved developmental gene family.

Authors:  D J Law; T Gebuhr; N Garvey; S I Agulnik; L M Silver
Journal:  Mamm Genome       Date:  1995-11       Impact factor: 2.957

8.  Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.

Authors:  Lori Rink; Yuliya Skorobogatko; Andrew V Kossenkov; Martin G Belinsky; Thomas Pajak; Michael C Heinrich; Charles D Blanke; Margaret von Mehren; Michael F Ochs; Burton Eisenberg; Andrew K Godwin
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

9.  BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.

Authors:  Weixing Zhao; Justin B Steinfeld; Fengshan Liang; Xiaoyong Chen; David G Maranon; Chu Jian Ma; Youngho Kwon; Timsi Rao; Weibin Wang; Chen Sheng; Xuemei Song; Yanhong Deng; Judit Jimenez-Sainz; Lucy Lu; Ryan B Jensen; Yong Xiong; Gary M Kupfer; Claudia Wiese; Eric C Greene; Patrick Sung
Journal:  Nature       Date:  2017-10-04       Impact factor: 49.962

10.  Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Vera M Abeler; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Oncol       Date:  2009-09-15       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.